These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29545753)

  • 1. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.
    Schindler EAD; Wallace RM; Sloshower JA; D'Souza DC
    Front Pharmacol; 2018; 9():177. PubMed ID: 29545753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics as preventive treatment in headache and chronic pain disorders.
    Schindler EAD
    Neuropharmacology; 2022 Sep; 215():109166. PubMed ID: 35718005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An introduction to psychedelic neuroscience.
    Calvey T; Howells FM
    Prog Brain Res; 2018; 242():1-23. PubMed ID: 30471677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic medicine: The biology underlying the persisting psychedelic effects.
    Kuypers KPC
    Med Hypotheses; 2019 Apr; 125():21-24. PubMed ID: 30902145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic Drugs in Biomedicine.
    Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV
    Trends Pharmacol Sci; 2017 Nov; 38(11):992-1005. PubMed ID: 28947075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Psychedelics Alleviate Symptoms of Cluster Headache and Accompanying Mental Health Problems? A Case Report Involving Hawaiian Baby Woodrose.
    Johnson S; Black QC
    J Psychoactive Drugs; 2020; 52(4):319-323. PubMed ID: 32375602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
    Atiq MA; Baker MR; Voort JLV; Vargas MV; Choi DS
    Psychopharmacology (Berl); 2024 May; ():. PubMed ID: 38743110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.
    Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS
    Int J Drug Policy; 2021 Dec; 98():103380. PubMed ID: 34329952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.
    Olson DE
    Biochemistry; 2022 Feb; 61(3):127-136. PubMed ID: 35060714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.
    Garcia-Romeu A; Darcy S; Jackson H; White T; Rosenberg P
    Curr Top Behav Neurosci; 2022; 56():287-317. PubMed ID: 34734390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis.
    Dourron HM; Strauss C; Hendricks PS
    Pharmacol Rev; 2022 Oct; 74(4):982-1027. PubMed ID: 36113878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations in assessing the abuse potential of psychedelics during drug development.
    Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D
    Neuropharmacology; 2023 Feb; 224():109352. PubMed ID: 36455646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.
    Tófoli LF; de Araujo DB
    Int Rev Neurobiol; 2016; 129():157-85. PubMed ID: 27503452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addiction specialists' attitudes toward psychedelics: A National Survey.
    Kim A; Suzuki J
    Am J Addict; 2023 Nov; 32(6):606-609. PubMed ID: 37550848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.